Log In
Print this Print this

fenofibrate/simvastatin (Cholib)

  Manage Alerts
Collapse Summary General Information
Company Abbott Laboratories
DescriptionFixed-dose combination of 145 mg fenofibrate and either 20 or 40 mg simvastatin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationDyslipidemia
Indication DetailsAdjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidemia to reduce triglycerides and increase HDL-C levels when LDL-C levels are adequately controlled with the corresponding dose of simvastatin monotherapy
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today